Tests oxygen delivery to the unventilated lung during lung cancer surgery
Studies a breathing approach in adults having surgery for lung cancer.
Plain-language title generated from the registry record
Registry title: Effect of Apneic Oxygenation of the Non-ventilated Lung During Lung Cancer Surgery.
Key facts
- Where
- Osijek, CroatiaSee the site
Where in Croatia
- University Hospital Center OsijekOsijek, CroatiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Osijek University Hospital
- Trial code
- NCT07393490
- Record updated
- 26 June 2026
- Original description
This study investigates the effect of apneic oxygenation of the non-ventilated lung on local and systemic inflammatory response during lung cancer surgery.Read full original descriptionShow less
The Effect of Apneic Oxygenation of the Non-ventilated Lung on the Expression of Hypoxia-inducible Factor-1 Alpha (HIF-1α) and Interleukin-6 (IL-6) in Lung Tissue During Lung Cancer Surgery.
This study investigates the effect of apneic oxygenation of the non-ventilated lung on local and systemic inflammatory response during lung cancer surgery.
Patients undergoing surgical resection of lung cancer often require one-lung ventilation during anaesthesia. This results in alveolar hypoxia accompanied by upregulated expression of inflammatory markers. Apneic oxygenation of the non-ventiladed lung may influence inflammatory processes and oxygenation during surgery. The aim of this study is to evaluate whether apneic oxygenation affects inflammatory markers in lung tissue and postoperative recovery in patients undergoing lung cancer surgery. The study is conducted at a single center and includes adult patients scheduled for elective lung cancer surgery. Data will be collected durig the perioperative period. The results of this study may contribute to improved anaesthetic management and patient outcomes during thoracic surgery.
Inclusion: Adults aged 18 years or older; Patients scheduled to undergo surgical resection of a single lung segment for lung cancer; Written informed consent provided.
Exclusion: Chronic corticosteroid therapy and/or other immunomodulatory treatments; Surgical procedure expected to last less than 2 hours; Severe pulmonary diseases, including:; Chronic obstructive pulmonary disease classified as GOLD stage 3-4 (Global Initiative for Chronic Obstructive Lung Disease); Severe asthma according to GINA classification (Global Initiative for Asthma), step 4; Severe interstitial lung disease defined by: Forced vital capacity (FVC) < 50% predicted, diffusing capacity of the lung for carbon monoxide (DLCO) < 40% predicted, presence of extensive pulmonary fibrosis on computed tomography (CT); New-onset intraoperative cardiac arrhythmias; Age younger than 18 years; Intraoperative hemodynamic instability, defined as: Mean arterial pressure < 60 mmHg for more than 30 minutes despite adequate volume resuscitation, requirement for high-dose vasopressor support (norepinephrine > 0.2 µg/kg/min); Significant intraoperative blood loss, defined as the need for transfusion of more than two units of packed red blood cells; Intraoperative ventilatory instability, defined as: Severe hypoxemia (PaO₂ < 60 mmHg or SpO₂ < 85% with FiO₂ 1.0), hypercapnia (PaCO₂ > 70 mmHg with pH < 7.2), inability to achieve adequate ventilation.